MedTrace Logo

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

NCT02441062 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2020-12-21

Study results available
· View outcomes & findings →

Summary

Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors.

The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.

Conditions

Interventions

DRUG

68Ga-DOTATOC PET/CT

Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors

Sponsors & Collaborators

  • University of Iowa

    collaborator OTHER

  • Sue O'Dorisio

    lead OTHER

Principal Investigators

  • Mary S O'Dorisio, MD, PhD · University of Iowa

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2020-01-20
Completion
2020-01-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02441062 on ClinicalTrials.gov